
Key Points
- Seizure scale: 165,000 units in total—90,000 ENDS devices and 75,000 refill cartridges—with an MSRP exceeding $1.47 million.
- Nature of violations: Lack of FDA premarket authorization (PMTA); products deemed “adulterated and misbranded” under the FD&C Act.
- Flavors involved: Blue Razz, Iced Lush, Blue Lightning, Gum Mint, Turkish Tobacco, Classic Tobacco, among others.
- Related enforcement: Intelligence support from CBP’s Chicago Field Office aided the interdiction; earlier Chicago operations seized about 4.7 million units (valued at ~$86.5 million), and last week the DOJ and FDA reported over 2.1 million illicit vaping products seized nationwide.
2Firsts, September 29, 2025 — U.S. Customs and Border Protection (CBP) announced that officers in the Minneapolis–St. Paul area recently inspected multiple pallets and discovered roughly 165,000 e-cigarette devices and refill cartridges—comprising 90,000 devices and 75,000 cartridges.
After a joint evaluation by CBP and the U.S. Food and Drug Administration (FDA), the products were determined to lack the FDA’s required premarket authorization and therefore cannot be legally sold in the United States. They were further classified as “adulterated” and “misbranded” under the FD&C Act and seized accordingly. The Manufacturer’s Suggested Retail Price (MSRP) for the shipments is estimated to exceed $1.47 million. All consignments reportedly originated in China and were destined for a wholesaler in California.

CBP noted that the interdiction benefited from intelligence sharing with the Chicago Field Office. The seized items included a variety of flavors such as Blue Razz, Iced Lush, Blue Lightning, Gum Mint, Turkish Tobacco, and Classic Tobacco. CBP said it will continue working with the FDA and other partners to identify and seize unsafe and illicit goods, and reminded importers and e-commerce buyers to ensure their purchases and importations comply with federal and state regulations.

Federal agencies have recently intensified enforcement nationally. Earlier this month, CBP, the U.S. Department of Health and Human Services (HHS), and the FDA conducted a joint operation in Chicago that seized approximately 4.7 million unauthorized e-cigarettes valued at about $86.5 million. Last week, the U.S. Department of Justice (DOJ) and FDA also announced coordinated actions across seven states that resulted in the seizure of more than 2.1 million illicit vaping products. (Read more: Largest E-Cigarette Seizure in U.S. History: Over 600,000 Products Confiscated from Midwest Goods Warehouse; Company Denies Violations, Calls FDA “Unfair”)
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com